Astilbin ameliorates intestinal inflammation and suppresses colorectal cancer cell proliferation by regulating NLRP3 inflammasome and nuclear factor-kappa B signaling pathway

Sep 22, 2026

Uploaded by Ivy

The inflammation-responsive NLRP3 inflammasome and nuclear factor-kappa B (NF-κB) dependent signaling pathways are linked to colorectal cancer (CRC) and inflammatory disorders. This study evaluates whether astilbin (AST) modulates anti-inflammatory NLRP3 and NF-κB molecular events to inhibit CRC progression. AST was tested on HCT116 and HT-29 cells for survival, apoptosis, and cell cycle effects, and in an AOM/DSS colitis-associated colon cancer mouse model for tumor burden and inflammation markers.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages23

Reading Time58 min

AccessFree to download

Abstract

Introduction

| Access this article online | | --- | | Quick Response Code: | | | | Website:
[www.ijp-online.com](www.ijp-online.com) | | DOI:
10.4103/ijp. ijp_678_24 | Department of General Surgery, Shanghai Songjiang Sijing Hospital, Shanghai, 1Department of Gastroenterology, Xi’an Aerospace General Hospital, 2Department of Oncology, Shaanxi Provincial Cancer Hospital, 3Department of Surgical, Shaanxi Kangfu Hospital, Xi’an, Shaanxi, China \#Lu Han and Xiao Zhong Deng are co‑first authors, they contributed equally to this work. Address for correspondence: Dr. Jinqing Hui, Department of Surgical, Shaanxi Kangfu Hospital, Xi’an, Shaanxi 710065, China. E-mail: huijinqing2023@ [sina.com](sina.com) Submitted: 08-Aug-2024 Revised: 09-Jun-2025 Accepted: 25-Oct-2025 Published: 07-Jan-2026 Research Article Astilbin ameliorates intestinal inflammation and suppresses colorectal cancer cell proliferation by regulating NLRP3 inflammasome and nuclear factor‑kappa B signaling pathway Lu Han\#, Xiao Zhong Deng1\#, Ya Li2, Jinqing Hui3 Abstract: OBJECTIVE: The inflammation‑responsive NLRP3 inflammasome and nuclear factor‑kappa B (NF‑κB) dependent signaling pathways are critically connected with inflammatory conditions and disorders such as colorectal cancer (CRC) . Where phytochemicals may be added as preventive natural supplements to control CRC. In this study, we investigated whether astilbin (AST) interacted with anti‑inflammatory NLRP3 and NF‑κB‑dependent molecular events in CRC. BACKGROUND: The network of growth signaling redox‑sensitive transcription factor NF‑κB interacting with the NLRP3 inflammasome in CRC progression needed targeted research. AST is aflavonol reported for anti‑inflammatory, immune‑suppressive, and antioxidant properties, which are sought to assess CRC growth inhibition through NF‑κB and NLRP3 . METHODS: AST was applied to HCT116 and HT‑29 cells of human origin to examine cell survival, apoptosis, progression, and DNA fragmentation to determine the analysis of gene and protein expression and molecular mechanisms. RESULTS: AST inhibits the proliferation of HCT116 and HT29, and both cell lines depend on IC50 values of 128 and 144 events. AST caused induction of apoptosis in CRC cells via intrinsic mechanism involving caspase‑9 and caspase‑3 activation and caused arrest of the G2/M phase cell cycle. AST (100 µm) inhibited colony formation abilities to 54% and wound healing to 62% in both cell lines. In the azoxymethane/dextran sodium sulfate (AOM/DSS)‑induced colitis‑associated colon cancer mice, the total tumor count was reduced from 14 to 4.3 by the AST 20 mg/kg group, significantly reducing the large tumor count. AST (20 mg/kg) suppressed the colonic inflammation as shown by decreased expression of NF‑κB (1.8‑fold) and NLRP3 (1.5‑fold) against the control (1.0‑fold) . AST restored colon length and histopathological changes caused by AOM/DSS. AST inhibited the production of COX‑2, INOS, and pro‑inflammatory cytokines and chemokines, especially interleukin‑6 (IL‑6), IL‑1β , and IL‑10, by approximately 50% at 20 mg/kg. AST suppressed intestinal tissue ASC and IL‑1β NLRP3 and NF‑kB by approximately 1.3 times compared to control. CONCLUSIONS: AST inhibited colorectal carcinoma growth by blocking the expression of NLRP3 and NF‑κB and inducing an apoptotic cascade and suppressing iNOS‑COX2 and IL‑1β as regulators of inflammation and growth signal. This study advocates the application of phytopharmaceutical supplements for the management of colorectal carcinoma. Keywords: Astilbin, colorectal cancer, inflammasome, NLRP3, nuclear factor‑kappa B, phytopharmacology This isan open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License (CC BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in anyway or used commercially without permission from the journal. [Fo

FAQs

What is the main biological target investigated in the study?

The study focuses on regulating the NLRP3 inflammasome and the NF-κB signaling pathway to reduce intestinal inflammation and colorectal cancer progression.

How does astilbin affect colorectal cancer cells in vitro?

Astilbin inhibits proliferation of HCT116 and HT-29 cells, induces apoptosis through an intrinsic caspase-9/caspase-3 mechanism, and causes G2/M cell-cycle arrest.

What effects does astilbin show in the AOM/DSS-induced mouse model?

Astilbin reduces tumor counts and suppresses colonic inflammation, including decreased NF-κB and NLRP3 expression and reduced inflammatory mediators such as COX-2, iNOS, and cytokines/chemokines (e.g., IL-6 and IL-1β).

Sep 22, 2026

Uploaded by Ivy